Composite measures in psoriatic arthritis: GRAPPA 2008

Journal of Rheumatology

Volumn 37, Issue 2, 2010, Pages 453-461

  Gladman, Dafna D ^a   Landewé, Robert ^b   McHugh, Neil J ^c   FitzGerald, Oliver ^d   Thaci, Diamant ^e   Coates, Laura ^f   Mease, Philip J ^g   Qureshi, Abrar A ^h   Krueger, Gerald G ⁱ   Ritchlin, Christopher T ^j   Kavanaugh, Arthur F ^k   Garg, Amit ^l  

^a UNIVERSITY OF TORONTO   (Canada)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ROYAL NATIONAL HOSPITAL FOR RHEUMATIC DISEASES   (United Kingdom)

^d ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^e GOETHE UNIVERSITY   (Germany)

^f UNIVERSITY OF LEEDS   (United Kingdom)

^g Seattle Rhumatology Associates   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Disease activity; Psoriasis; Psoriatic arthritis

Indexed keywords

ADALIMUMAB; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR;

ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL ASSESSMENT; COMORBIDITY; DISEASE ACTIVITY; DRUG EFFICACY; ENTHESITIS; HEALTH CARE ORGANIZATION; HUMAN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; PUVA; RHEUMATOID ARTHRITIS; SACROILIITIS; SCORING SYSTEM; SPONDYLITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; UNITED KINGDOM;

ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; HUMANS; JOINTS; PSORIASIS; SEVERITY OF ILLNESS INDEX;

EID: 76649084875     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090956     Document Type: Article

References (19)

1. van der Heijde DM, van 't Hof M, van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993;20:579-81.
2. Landewe R, van der Heijde D, van der Linden S, Boers M. Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: a comparison with the original DAS remission. Ann Rheum Dis 2006;65:637-41.
3. Pham T, Landewe R, van der Linden S, Dougados M, Sieper J, Braun J, et al. An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis. Ann Rheum Dis 2006;65:1620-5.
4. Lukas C, Landewe R, Sieper J, Dougados M, Davis J, Braun J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:18-24.
5. Isenberg DA, Rahman A, Allen E, Farewell V, Akil M, Bruce IN, et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology 2005;44:902-6.
6. Merrill JT, Buyon JP, Furie R, Latinis KM, Gordon C, Hsieh H, et al. Assessment of flares in lupus (SLE) patients in a placebo-controlled randomized phase II/III study of rituximab (EXPLORER) [abstract]. Ann Rheum Dis 2009;68 Suppl 3:71.
7. Fransen J, Antoni C, Mease PJ, Uter W, Kavanaugh A, Kalden JR, et al. Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis 2006;65:1373-8.
8. Gladman DD, Tom BD, Mease PJ, Farewell VT. Response criteria for psoriatic arthritis I: derivation of models for response [abstract]. Ann Rheum Dis 2008;67 Suppl 2:526.
9. Gladman DD, Tom BD, Mease PJ, Farewell VT. Response criteria for psoriatic arthritis II: developing and comparing response criteria for PsA [abstract]. Ann Rheum Dis 2008;67 Suppl 2:526.
10. Mumtaz A, Gallagher P, Kirby B, Coates LC, Waxman R, Helliwell P, et al. Development of a composite disease activity score in psoriatic arthritis [abstract]. Rheumatology 2009;48 Suppl:i57.
11. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007;370:263-71.
12. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978;157:238-44.
13. Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol 2004;51:563-9.
14. Chandran V, Gottlieb AB, Cook RJ, Duffin K, Garg A, Helliwell PS, et al. International multi-center psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis. Arthritis Care Res 2009;61:1235-42.
15. Berth-Jones J, Grotzinger K, Rainville C, Pham B, Huang J, Daly S, et al. A study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician's Global Assessment and Lattice System Physician's Global Assessment. Br J Dermatol 2006;155:707-13.
16. Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 2009 [Epub ahead of print].
17. Wells GA, Boers M, Shea B, Brooks PM, Simon LS, Strand CV, et al. Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol 2005;32:2016-24.
18. Coates LC, Schentag C, Lee KA, Chandran V, Cook RJ, Gladman DD. Frequency and predictors of minimal disease activity in an observational PsA cohort [abstract]. Arthritis Rheum 2008;58:3997.
19. Kavanaugh AF, Ritchlin CT. Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol 2006;33:1417-21.